Nuwellis (NUWE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
2 Apr, 2026Executive summary
The annual meeting is scheduled for April 28, 2026, as a virtual event, with stockholders able to vote and participate online.
Two main proposals are up for vote: election of two Class I directors and ratification of Baker Tilly as the independent auditor for 2026.
Only holders of common stock as of March 24, 2026, are eligible to vote.
The Board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1: Elect two Class I directors (Martin Emerson and David McDonald) for three-year terms expiring in 2029.
Proposal 2: Ratify Baker Tilly US, LLP as the independent registered public accounting firm for fiscal year 2026.
No other shareholder proposals or nominations were received for this meeting.
Voting can be done online, by phone, or by mail, and proxies can be revoked before the meeting.
Board of directors and corporate governance
The Board consists of five directors divided into three staggered classes.
Majority of directors are independent per Nasdaq rules; all committee members are independent.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters and responsibilities.
Annual performance evaluations and succession planning are conducted.
Directors are expected to attend all meetings, and the Board met 16 times in 2025.
Latest events from Nuwellis
- Best-efforts offering targets $4.4M for working capital, with high dilution and ongoing losses.NUWE
Registration filing4 Jun 2026 - Pediatric and critical care growth, innovation, and operational discipline drive revenue momentum.NUWE
Investor presentation2 Jun 2026 - Offering up to $4.4M in equity and warrants, with high dilution and operational risks.NUWE
Registration filing29 May 2026 - Up to $4.4M sought via equity and warrants to fund operations amid high product and financial risk.NUWE
Registration filing22 May 2026 - Revenue up 26% to $2.4M, gross margin 70.1%, net loss $4.5M, with new patents and capital needs.NUWE
Q1 202615 May 2026 - Updated share count, board changes, and voting details for the April 2026 Annual Meeting.NUWE
Proxy filing6 Apr 2026 - Q4 revenue and margin gains, strategic moves, and new leadership set up 2026 growth.NUWE
Q4 202520 Mar 2026 - Innovative fluid management platform targets $4.2B market with strong clinical and financial momentum.NUWE
Investor presentation10 Mar 2026 - Registering 4.28M shares for resale, proceeds from warrant exercises support working capital.NUWE
Registration Filing4 Feb 2026